サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1777642

タイプ2糖尿病治療の世界市場

Type 2 Diabetes Mellitus Treatment

出版日
ページ情報
英文 381 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
タイプ2糖尿病治療の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 381 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

タイプ2糖尿病治療の世界市場は2030年までに806億米ドルに達する見込み

2024年に596億米ドルと推定されるタイプ2糖尿病治療の世界市場は、2024～2030年の分析期間においてCAGR 5.2%で成長し、2030年には806億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるインスリンは、CAGR 4.1%を記録し、分析期間終了時には284億米ドルに達すると予想されます。DPP-4阻害剤セグメントは、分析期間中にCAGR 6.8%の成長が見込まれます。

米国市場は162億米ドルと推定、中国はCAGR 8.0%で成長すると予測

米国のタイプ2糖尿病治療市場は、2024年に162億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに159億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6%と5.1%と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

タイプ2糖尿病治療市場動向と促進要因のまとめ

2型糖尿病治療市場は次世代治療薬によってどのように進化しているか？

2型糖尿病（T2DM）は依然として世界の健康課題であり、座りがちなライフスタイル、食生活の乱れ、肥満などにより有病率が上昇しています。従来の治療戦略には、経口抗糖尿病薬（OADs）、インスリン療法、生活習慣の改善が含まれます。しかし、GLP-1受容体作動薬、SGLT2阻害薬、遺伝子ベースの治療薬の進歩が糖尿病管理を変革し、より優れた血糖コントロールと心血管リスクの低減を提供しています。AIを活用したデジタル治療薬や持続血糖モニタリング（CGM）デバイスの登場により、個別化治療アプローチがさらに強化されつつあります。しかし、薬剤の価格、患者のアドヒアランス、長期的な副作用などの課題は、治療成績に影響を与え続けています。プレシジョン・メディシンの進歩に伴い、将来の糖尿病治療は革新的な薬剤製剤とデジタルヘルスソリューションをどのように統合していくのだろうか。

どのような技術革新が2型糖尿病治療を前進させているのか？

週1回注射可能なGLP-1受容体作動薬、経口セマグルチド製剤、および併用療法の開発により、患者のアドヒアランスと治療効果が向上しています。AIを活用したインスリン投与アルゴリズムとCGM一体型インスリンポンプは、グルコースコントロールを最適化し、低血糖のリスクを低減しています。さらに、膵β細胞の再生やCRISPRを用いた治療法などの遺伝子編集技術に関する調査により、糖尿病を回復させる新たな可能性が開かれつつあります。

なぜ2型糖尿病治療の需要が増加しているのか？

糖尿病有病率の上昇、デジタルヘルス・ソリューションの採用増加、予防医療重視の高まりが、革新的な糖尿病治療への需要を後押ししています。糖尿病に対する認識を高め、手ごろな薬へのアクセスを促進する政府の取り組みが、市場の成長をさらに後押ししています。さらに、オンライン薬局や遠隔医療プラットフォームの拡大が、患者の糖尿病治療へのアクセスを向上させています。

2型糖尿病治療市場の成長を促進する要因は何か？

個別化された糖尿病管理の進歩、AI主導のデジタル治療薬の採用拡大、再生医療への投資の増加、糖尿病予防戦略に対する消費者の意識の高まりなどが市場の拡大に寄与しています。糖尿病治療が患者中心のテクノロジー主導型ソリューションへとシフトする中、T2DM治療の将来は、よりアクセスしやすく、効率的で、予防的なものになると予想されます。

セグメント

薬剤クラス別（インスリン製剤、DPP-4阻害剤、GLP-1受容体作動薬、SGLT2阻害剤、その他）;投与経路別（経口剤、皮下投与剤、静脈内投与剤）;販売チャネル別（小売薬局、病院薬局、その他）

調査対象企業の例

  • Abbott Laboratories
  • Acon Laboratories Inc.
  • Adocia
  • Akros Pharma
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • Dexcom Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • MannKind Corporation
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33195

Global Type 2 Diabetes Mellitus Treatment Market to Reach US$80.6 Billion by 2030

The global market for Type 2 Diabetes Mellitus Treatment estimated at US$59.6 Billion in the year 2024, is expected to reach US$80.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Insulin, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$28.4 Billion by the end of the analysis period. Growth in the DPP-4 Inhibitors segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$16.2 Billion While China is Forecast to Grow at 8.0% CAGR

The Type 2 Diabetes Mellitus Treatment market in the U.S. is estimated at US$16.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$15.9 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Type 2 Diabetes Mellitus Treatment Market Trends & Drivers Summarized

How Is the Type 2 Diabetes Treatment Market Evolving with Next-Generation Therapies?

Type 2 diabetes mellitus (T2DM) remains a global health challenge, with rising prevalence due to sedentary lifestyles, poor dietary habits, and obesity. Traditional treatment strategies include oral antidiabetic drugs (OADs), insulin therapy, and lifestyle modifications. However, advancements in GLP-1 receptor agonists, SGLT2 inhibitors, and gene-based therapies are transforming diabetes management, offering better glycemic control and reduced cardiovascular risks. The emergence of AI-driven digital therapeutics and continuous glucose monitoring (CGM) devices is further enhancing personalized treatment approaches. However, challenges such as drug affordability, patient adherence, and long-term side effects continue to impact treatment outcomes. As precision medicine advances, how will the future of diabetes care integrate innovative drug formulations and digital health solutions?

What Technological Innovations Are Advancing Type 2 Diabetes Treatment?

The development of once-weekly injectable GLP-1 receptor agonists, oral semaglutide formulations, and combination therapies is improving patient adherence and treatment efficacy. AI-powered insulin dosing algorithms and CGM-integrated insulin pumps are optimizing glucose control, reducing the risk of hypoglycemia. Additionally, research into pancreatic beta-cell regeneration and gene-editing techniques such as CRISPR-based therapies is opening new possibilities for reversing diabetes.

Why Is the Demand for Type 2 Diabetes Treatment Increasing?

The rising prevalence of diabetes, increasing adoption of digital health solutions, and growing emphasis on preventive care are fueling demand for innovative diabetes treatments. Government initiatives promoting diabetes awareness and access to affordable medications are further supporting market growth. Additionally, the expansion of online pharmacies and telemedicine platforms is improving patient access to diabetes care.

What Factors Are Driving the Growth of the Type 2 Diabetes Treatment Market?

The market is expanding due to advancements in personalized diabetes management, increasing adoption of AI-driven digital therapeutics, rising investment in regenerative medicine, and growing consumer awareness of diabetes prevention strategies. As diabetes care shifts toward patient-centric and technology-driven solutions, the future of T2DM treatment is expected to be more accessible, efficient, and preventive.

SCOPE OF STUDY:

The report analyzes the Type 2 Diabetes Mellitus Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others); Administration Route (Oral, Subcutaneous, Intravenous); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Acon Laboratories Inc.
  • Adocia
  • Akros Pharma
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • Dexcom Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • MannKind Corporation
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Type 2 Diabetes Mellitus Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Surge in Type 2 Diabetes Prevalence Drives Sustained Therapeutic Demand
    • Growing Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors Improves Treatment Outcomes
    • Shift Toward Early Combination Therapy Enhances Market for Multi-Drug Regimens
    • Digital Therapeutics and Remote Monitoring Expand Patient Engagement and Adherence
    • Continuous Glucose Monitoring Integration in Care Pathways Enhances Personalized Treatment
    • Innovation in Oral Peptide Delivery Systems Opens Non-Injectable Treatment Possibilities
    • Increasing Focus on Cardiovascular and Renal Comorbidity Management Expands Use of New-Age Antidiabetics
    • Expansion of Health Insurance Coverage in Emerging Markets Improves Drug Accessibility
    • Growing Investment in Artificial Pancreas and Closed-Loop Insulin Delivery Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Type 2 Diabetes Mellitus Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Type 2 Diabetes Mellitus Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for DPP-4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for DPP-4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for DPP-4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for GLP-1 Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for GLP-1 Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for GLP-1 Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for SGLT2 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for SGLT2 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • JAPAN
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • CHINA
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • EUROPE
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Type 2 Diabetes Mellitus Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • FRANCE
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • GERMANY
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Type 2 Diabetes Mellitus Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • INDIA
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Type 2 Diabetes Mellitus Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Type 2 Diabetes Mellitus Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • AFRICA
    • Type 2 Diabetes Mellitus Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Type 2 Diabetes Mellitus Treatment by Drug Class - Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Drug Class - Percentage Breakdown of Value Sales for Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Other Distribution Channels and Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Type 2 Diabetes Mellitus Treatment by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Type 2 Diabetes Mellitus Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030

IV. COMPETITION